<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04869631</url>
  </required_header>
  <id_info>
    <org_study_id>EA4/235/20</org_study_id>
    <nct_id>NCT04869631</nct_id>
  </id_info>
  <brief_title>Screening for Amyloidosis Before Aortic Valve Elective Replacement</brief_title>
  <acronym>SAVER</acronym>
  <official_title>Screening for Amyloidosis Before Aortic Valve Elective Replacement (SAVER)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charite University, Berlin, Germany</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Deutsches Herzzentrum Berlin, Klinik für Innere Medizin - Kardiologie</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Klinik für Neurologie mit Experimenteller Neurologie, Charité - Universitätsmedizin Berlin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charite University, Berlin, Germany</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Previous studies detected that up to 15% of patients undergoing aortic valve replacement&#xD;
      (AVR) for degenerative aortic stenosis have concomitant transthyretin amyloidosis (ATTR)&#xD;
      cardiomyopathy (Castano, 2017). The aim of this study is to investigate the effectivity and&#xD;
      practicability of a systematic ATTR-Screening in patients undergoing planned AVR. Moreover,&#xD;
      we plan to develop a screening algorithm to detect ATTR in aortic stenosis (AS).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Untreated cardiac amyloidosis is accompanied with an impaired prognosis. Amyloidosis is often&#xD;
      associated with ventricular hypertrophy which leads to severe heart failure and occurs&#xD;
      frequently in conjunction with bradycardic or tachycardic malignant arrhythmia. Patients with&#xD;
      degenerative aortic valve stenosis suffer more frequently from cardiac ATTR. However, it&#xD;
      remains unclear whether the development of aortic stenosis is promoted by ATTR. Due to very&#xD;
      similar symptoms (shortness of breath during physical exertion, reduced walking distance)&#xD;
      diagnosis of aortic valve stenosis is more often diagnosed in a typical cohort of patients&#xD;
      aged between 70-80 years but, in contrast, leads to underdiagnosis of patients with&#xD;
      additional cardiac amyloidosis. Six to fifteen percent of patients with aortic valve&#xD;
      replacement due to degenerative aortic valve stenosis exhibit a cardiac amyloidosis. Since&#xD;
      cardiac amyloidosis without therapeutic intervention is associated with significantly reduced&#xD;
      life expectancy, it can be assumed that these patients will not benefit to the same extent&#xD;
      from the AVR alone as patients without ATTR. New therapeutic approaches for patients&#xD;
      exhibiting ATTR lead to a reduction of mortality and hospitalizations. The primary aim of&#xD;
      this study is to establish a simple ATTR screening tool in patients with planned AVR in the&#xD;
      clinical routine and, furthermore, to compare the clinical course following AVR between&#xD;
      patients with and without ATTR.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 1, 2021</start_date>
  <completion_date type="Anticipated">January 28, 2028</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number/ proportion of ATTR cases identified by systematic screening</measure>
    <time_frame>Enrolment period: 18 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Amyloidosis</condition>
  <condition>Aortic Valve Stenosis</condition>
  <arm_group>
    <arm_group_label>Aortic valve stenosis undergoing aortic valve replacement</arm_group_label>
    <description>Aortic valve stenosis undergoing aortic valve replacement.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>The outcome of an intervention is not evaluated, but aortic stenosis and additional amyloidosis are compared.</intervention_name>
    <description>We aim to compare patients with aortic valve stenosis with and without cardiac amyloidosis.</description>
    <arm_group_label>Aortic valve stenosis undergoing aortic valve replacement</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients &gt;40 years with aortic valve stenosis who are scheduled to undergo interventional&#xD;
        or surgical aortic valve replacement at Deutsches Herzzentrum Berlin or Charité -&#xD;
        Universitätsmedizin Berlin during a recruiting period of 18 months; in total approximately&#xD;
        1500 patients.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age ≥40 years&#xD;
&#xD;
          -  written informed consent from the patient or of his/her legal guardian&#xD;
&#xD;
          -  hospitalization for AVR due to degenerative aortic valve stenosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  hemodynamically unstable patient&#xD;
&#xD;
          -  severe co-morbidities with an estimated life expectancy of &lt;1 year&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Isabel Mattig, MD</last_name>
    <phone>+49 30 450 513 142</phone>
    <email>isabel.mattig@charite.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Daniel Messroghli, MD</last_name>
    <phone>+49 30 4593 2400</phone>
    <email>dmessroghli@DHZB.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Isabel Mattig, MD</last_name>
      <phone>+49 30 450 513 142</phone>
      <email>isabel.mattig@charite.de</email>
    </contact>
    <investigator>
      <last_name>Daniel Messroghli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fabian Knebel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Isabel Mattig, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katrin Hahn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Wrede-Wihl Katrin</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://amyloidosis-center.charite.de/</url>
    <description>Amyloidosis center of the Charité</description>
  </link>
  <reference>
    <citation>Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, Kristen AV, Grogan M, Witteles R, Damy T, Drachman BM, Shah SJ, Hanna M, Judge DP, Barsdorf AI, Huber P, Patterson TA, Riley S, Schumacher J, Stewart M, Sultan MB, Rapezzi C; ATTR-ACT Study Investigators. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2018 Sep 13;379(11):1007-1016. doi: 10.1056/NEJMoa1805689. Epub 2018 Aug 27.</citation>
    <PMID>30145929</PMID>
  </reference>
  <reference>
    <citation>Nitsche C, Aschauer S, Kammerlander AA, Schneider M, Poschner T, Duca F, Binder C, Koschutnik M, Stiftinger J, Goliasch G, Siller-Matula J, Winter MP, Anvari-Pirsch A, Andreas M, Geppert A, Beitzke D, Loewe C, Hacker M, Agis H, Kain R, Lang I, Bonderman D, Hengstenberg C, Mascherbauer J. Light-chain and transthyretin cardiac amyloidosis in severe aortic stenosis: prevalence, screening possibilities, and outcome. Eur J Heart Fail. 2020 Oct;22(10):1852-1862. doi: 10.1002/ejhf.1756. Epub 2020 Feb 20.</citation>
    <PMID>32078212</PMID>
  </reference>
  <reference>
    <citation>Castaño A, Narotsky DL, Hamid N, Khalique OK, Morgenstern R, DeLuca A, Rubin J, Chiuzan C, Nazif T, Vahl T, George I, Kodali S, Leon MB, Hahn R, Bokhari S, Maurer MS. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017 Oct 7;38(38):2879-2887. doi: 10.1093/eurheartj/ehx350.</citation>
    <PMID>29019612</PMID>
  </reference>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 28, 2021</study_first_submitted>
  <study_first_submitted_qc>April 28, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>May 3, 2021</last_update_submitted>
  <last_update_submitted_qc>May 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charite University, Berlin, Germany</investigator_affiliation>
    <investigator_full_name>Isabel Mattig</investigator_full_name>
    <investigator_title>Project lead</investigator_title>
  </responsible_party>
  <keyword>Cardiac Amyloidosis</keyword>
  <keyword>Transthyretin Amyloidosis</keyword>
  <keyword>ATTR</keyword>
  <keyword>Aortic Stenosis</keyword>
  <keyword>Screening</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

